Agilent Technologies Introduces Dako Omnis Family, Revolutionizing Pathology Labs with Customized Solutions.
PorAinvest
miércoles, 6 de agosto de 2025, 6:47 pm ET1 min de lectura
A--
The new instruments offer a tailored portfolio, allowing labs to select configurations that best meet their needs. The Dako Omnis 110 is built for precision in low-medium volume labs, delivering up to 110 IHC slides per day with dependable performance. The Dako Omnis 165 is engineered for efficiency in medium-high volume labs, delivering up to 165 IHC slides per day with seamless consistency. The Dako Omnis 165 Duo is designed for ultimate flexibility in medium-high volume labs, delivering simultaneous IHC and ISH with maximum throughput and confidence [1].
All models feature continuous, case-based processing and shared reagents, enabling labs to streamline workflows and reduce turnaround times. Additionally, a newly integrated direct connection for de-ionized water and non-hazardous waste further reduces handling time and operational interruptions [1].
The new Dako Omnis family was developed in response to the increasing pressure pathology labs face due to rising test volumes, limited staffing, and growing diagnostic complexity. Built on customer feedback, these instruments are designed to simplify workflows, enhance diagnostic efficiency, and help labs deliver timely, high-quality results [1].
The new Agilent Dako Omnis family of instruments will debut at major industry events, including the European Congress of Pathology (ECP) from September 6–10, and the National Society for Histotechnology (NSH) from September 26–30. Initial availability will be to the U.S., Europe, and Australia [1].
References:
[1] https://www.businesswire.com/news/home/20250804514299/en/Agilent-Expands-the-Dako-Omnis-Family-with-Three-New-Models-to-Meet-Evolving-Pathology-Lab-Needs
[2] https://www.morningstar.com/news/business-wire/20250804514299/agilent-expands-the-dako-omnis-family-with-three-new-models-to-meet-evolving-pathology-lab-needs
[3] https://www.webwire.com/ViewPressRel.asp?aId=341989
Agilent Technologies has introduced the Dako Omnis family of instruments, featuring three models: Agilent Dako Omnis 110, 165, and 165 Duo. The models offer flexibility in staining solutions based on lab volume, workflow, and diagnostic requirements. The instruments feature continuous, case-based processing and shared reagents, streamlining workflows and reducing turnaround times. The direct connection for de-ionized water and non-hazardous waste reduces handling time and operational interruptions. Agilent's solutions are built on customer feedback, addressing challenges such as rising test volumes and limited staffing.
Agilent Technologies Inc. (NYSE: A) has announced the introduction of its Dako Omnis family of instruments, featuring three new models: Agilent Dako Omnis 110, 165, and 165 Duo. These models are designed to meet the evolving needs of pathology laboratories of all sizes, providing flexibility in staining solutions based on lab volume, workflow, and diagnostic requirements [1].The new instruments offer a tailored portfolio, allowing labs to select configurations that best meet their needs. The Dako Omnis 110 is built for precision in low-medium volume labs, delivering up to 110 IHC slides per day with dependable performance. The Dako Omnis 165 is engineered for efficiency in medium-high volume labs, delivering up to 165 IHC slides per day with seamless consistency. The Dako Omnis 165 Duo is designed for ultimate flexibility in medium-high volume labs, delivering simultaneous IHC and ISH with maximum throughput and confidence [1].
All models feature continuous, case-based processing and shared reagents, enabling labs to streamline workflows and reduce turnaround times. Additionally, a newly integrated direct connection for de-ionized water and non-hazardous waste further reduces handling time and operational interruptions [1].
The new Dako Omnis family was developed in response to the increasing pressure pathology labs face due to rising test volumes, limited staffing, and growing diagnostic complexity. Built on customer feedback, these instruments are designed to simplify workflows, enhance diagnostic efficiency, and help labs deliver timely, high-quality results [1].
The new Agilent Dako Omnis family of instruments will debut at major industry events, including the European Congress of Pathology (ECP) from September 6–10, and the National Society for Histotechnology (NSH) from September 26–30. Initial availability will be to the U.S., Europe, and Australia [1].
References:
[1] https://www.businesswire.com/news/home/20250804514299/en/Agilent-Expands-the-Dako-Omnis-Family-with-Three-New-Models-to-Meet-Evolving-Pathology-Lab-Needs
[2] https://www.morningstar.com/news/business-wire/20250804514299/agilent-expands-the-dako-omnis-family-with-three-new-models-to-meet-evolving-pathology-lab-needs
[3] https://www.webwire.com/ViewPressRel.asp?aId=341989

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios